Nature 2021 Dec 15
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Abstract
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal junction adenocarcinomas1-3. More than a decade ago, combination therapy with the anti-HER2 antibody trastuzumab and chemotherapy became the standard first-line treatment for patients with these types of tumours4. Although adding the anti-programmed death 1 (PD-1) antibody pembrolizumab to chemotherapy does not significantly improve efficacy in advanced HER2-negative gastric cancer5, there are preclinical6-19 and clinical20,21 rationales for adding pembrolizumab in HER2-positive disease. Here we describe results of the protocol-specified first interim analysis of the randomized, double-blind, placebo-controlled phase III KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for unresectable or metastatic, HER2-positive gastric or gastro-oesophageal junction adenocarcinoma22 ( https://clinicaltrials.gov , NCT03615326). We show that adding pembrolizumab to trastuzumab and chemotherapy markedly reduces tumour size, induces complete responses in some participants, and significantly improves objective response rate.
Related Questions
What initial systemic approach will you recommend for metastatic pMMR HER2-positive esophageal/GEJ/gastric adenocarcinoma with PDL1 of 0?
FOLFOX-trastuzumab-pembrolizumab is consistent with the 2023 Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline (Shah et al., PMID 36603169). In KEYNOTE-811, a response benefit was shown by adding pembrolizumab to trastuzumab plus chemotherapy. In this trial, 13%...
What chemotherapy backbone would you use with trastuzumab in patients with HER2+ esophagogastric cancer that relapse after perioperative FLOT4?
As with many of these head-scratchers, there's no right answer here. But, I would begin from the starting point that the current standard-of-care for 1st-line treatment of Her2 positive GEJ/gastric cancer is pembrolizumab/trastuzumab and a fluoropyrimidine/platinum doublet, as the question acknowled...
What is the optimal management of patients with gastroesophageal cancer who progress to metastatic disease during preoperative FLOT?
As we all know, peri-operative FLOT is considered a standard-of-care for locally advanced GEJ/gastric adenocarcinomas (at least the vast majority of tumors that are MMR proficient/MSS). In my experience, actual progression of a carefully staged locally advanced cancer to metastatic disease during pr...